Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiotherapy, and surgery in adult and pediatric patients. GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron Accord is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways.

- Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting: decreases the incidence of nausea after surgery. - Hyper‑emesis gravidarum: may be used when conventional therapy is insufficient. - Nausea due to gastro‑intestinal disorders: provides symptomatic relief in selected cases.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools in some patients. - Fatigue: general tiredness. - Dizziness: transient light‑headedness. - Injection site pain: localized discomfort if administered intravenously.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation may occur. - Severe hypersensitivity: rash, itching, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances. - Neuroleptic malignant‑like syndrome: extremely rare neurological reaction.

Ondansetron should be used with caution in patients with known cardiac conduction abnormalities or electrolyte imbalances.

- Cardiac monitoring: obtain baseline ECG in at-risk patients. - Electrolyte assessment: correct potassium or magnesium deficits before use. - Drug interactions: review concomitant medications for QT‑prolonging potential. - Pregnancy: weigh benefits against potential risks; use only if clearly needed. - Breastfeeding: consider infant exposure; monitor if administered to nursing mothers. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Ondansetron may interact with several drug classes, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Certain antipsychotics (e.g., ziprasidone, haloperidol): additive effect on cardiac repolarization. - Macrolide antibiotics (e.g., erythromycin): may enhance QT‑interval changes.

Moderate Interactions (Monitor Closely): - Tricyclic antidepressants: potential for additive serotonergic activity. - Serotonergic agents (e.g., SSRIs, SNRIs, triptans): monitor for serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): may increase ondansetron plasma levels.